Supporting the limited role of IGF1R and IR as a target in TNBC, linsitinib, an IGF1R/IR small molecule inhibitor, failed to block tumour formation in vivo and additionally, had no significant effect on tumour growth. Here, IGF1R is linked to neoplasm.